/C O R R E C T I O N -- Altesa Biosciences Inc./

ConferencepositiveVapendavirPositive

AI Analysis

Summary

Altesa Biosciences presented clinical data at the European Respiratory Society International Congress 2026 showing that vapendavir significantly reduces key inflammatory biomarkers in rhinovirus-challenged COPD patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Novel clinical data demonstrated vapendavir significantly reduces key inflammatory biomarkers in rhinovirus-challenged COPD patients

Importance:5/10

Sentiment:

0.70

clinical dataCOPDrhinovirusinflammatory biomarkersconference presentationEuropean Respiratory Society

Related Companies

$ISCO

Read the original article

Published by PR Newswire Biotech on September 9, 2026 4:38 PM

Read Original